Teladoc, Inc. (TDOC) Rating Reiterated by Piper Jaffray Companies
Teladoc, Inc. (NYSE:TDOC)‘s stock had its “buy” rating reiterated by investment analysts at Piper Jaffray Companies in a report issued on Friday. They currently have a $32.00 price target on the health services provider’s stock. Piper Jaffray Companies’ price target points to a potential downside of 8.44% from the stock’s previous close.
Several other brokerages also recently weighed in on TDOC. TheStreet downgraded Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd. William Blair reiterated an “outperform” rating on shares of Teladoc in a research note on Tuesday, June 20th. Canaccord Genuity reiterated a “buy” rating and issued a $42.00 target price (up from $34.00) on shares of Teladoc in a research note on Tuesday, June 20th. Chardan Capital lifted their target price on Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, June 20th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $27.00 target price on shares of Teladoc in a research note on Monday, June 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $32.77.
Shares of Teladoc (NYSE TDOC) opened at 34.95 on Friday. Teladoc has a 12-month low of $13.49 and a 12-month high of $36.90. The firm’s market cap is $1.90 billion. The company’s 50 day moving average price is $31.90 and its 200-day moving average price is $24.09.
Teladoc (NYSE:TDOC) last released its quarterly earnings results on Monday, May 8th. The health services provider reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $42.90 million for the quarter, compared to the consensus estimate of $42.22 million. Teladoc had a negative return on equity of 24.73% and a negative net margin of 53.58%. The firm’s quarterly revenue was up 59.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.40) EPS. On average, equities research analysts anticipate that Teladoc will post ($0.88) EPS for the current year.
WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/07/17/teladoc-inc-tdoc-rating-reiterated-by-piper-jaffray-companies.html.
In other news, insider Michael H. King sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 19th. The stock was sold at an average price of $25.75, for a total value of $128,750.00. Following the completion of the sale, the insider now directly owns 61,459 shares of the company’s stock, valued at approximately $1,582,569.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Hirschhorn sold 59,100 shares of the firm’s stock in a transaction that occurred on Wednesday, April 19th. The shares were sold at an average price of $25.46, for a total value of $1,504,686.00. Following the completion of the sale, the vice president now directly owns 180,887 shares of the company’s stock, valued at $4,605,383.02. The disclosure for this sale can be found here. Insiders sold a total of 232,480 shares of company stock valued at $6,439,354 over the last three months. Insiders own 5.94% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Driehaus Capital Management LLC acquired a new stake in Teladoc during the first quarter valued at approximately $6,411,000. Blair William & Co. IL acquired a new stake in Teladoc during the first quarter valued at approximately $218,000. State Street Corp boosted its stake in Teladoc by 2.5% in the fourth quarter. State Street Corp now owns 381,703 shares of the health services provider’s stock valued at $6,309,000 after buying an additional 9,146 shares in the last quarter. FMR LLC boosted its stake in Teladoc by 35.0% in the fourth quarter. FMR LLC now owns 3,075,000 shares of the health services provider’s stock valued at $50,738,000 after buying an additional 796,647 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Teladoc by 8,826.7% in the first quarter. JPMorgan Chase & Co. now owns 1,606,535 shares of the health services provider’s stock valued at $40,163,000 after buying an additional 1,588,538 shares in the last quarter. 93.76% of the stock is owned by institutional investors and hedge funds.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.